Emergent Biosolutions (NYSE:EBS) reported fourth-quarter and full-year 2025 results on a Feb. 26, 2026 earnings call, with ...

Emergent BioSolutions faces a sharp reset in 2026 guidance, with revenue projected well below prior expectations. Read why EBS stock is rated hold.

Shares of Emergent Biosolutions fell after the company widened its loss and logged lower revenue during the fourth quarter. The stock sank 23%, to $8.58, in premarket trading Friday. Through ...

Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors authorized the repurchase of up to $50 million of the company’s common stock on or before March 31, 2027. This ...

Adjusted gross margin is expected to land between 45% and 47%. Adjusted EBITDA is anticipated to be between $135 million to $155 million. Net income is expected to be between a loss of $30 million and ...

Emergent BioSolutions (NYSE: EBS) today announced a series of new contracts and a contract modification with the Public Health Agency of Canada (PHAC) and the Department of National Defence (DND) to ...

Fourth Quarter 2025 Total Revenues of $148.7 million; Full Year 2025 Total Revenues of $742.9 millionFourth Quarter 2025 Net Loss of $54.6 million and Net Loss Margin of 37%Full Year 2025 Net Income ...

ARR Milestone Comes as Emergent Launches Mobile App So Billions Worldwide Can Build Software on the Go ...

Emergent BioSolutions Inc. EBS stock rose Friday following the FDA approval of new multipack configurations of ...

At the NDTV Ind.AI Summit, Mukund Jha, CEO of Emergent Labs, discussed how AI-driven platforms are making software ...